Scientists identify a new group of molecules that could slow tumor growth in patients with cancer of the prostate -
patients with prostate cancer were offered hope According to scientists from Newcastle University, UK, have identified a new group of molecules that could be targeted to slow tumor growth.
experts used advanced screening technique that found hundreds of genes were affected by the male hormone testosterone. It is believed this could lead to new diagnostic tests and treatments
Among the 700 genes identified is an important body that add sugar groups -. Known as glycans - on the surface of cancer cells in the prostate. This group has never been studied before.
Results of the research, published in EBioMedicine , suggest that testosterone changes glycans to make cancer cells more likely to survive, grow and spread to other parts of the body.
scientists say that there is the potential to target these glycans that could stop the growth and spread of tumors and save lives. .
Dr. Jennifer Munkley, associate researcher at the Institute of Medical Genetics, University of Newcastle, co-directed the three-year research project with Professor David Elliott
She said: "Our results are very important for future treatments because they identify a new group of molecules in prostate cancer that could be targeted therapeutically.
" now, we have identified these glycans, we will able to develop strategies to inhibit and help patients with this condition.
"processing targeting glycans sugar groups have been developed for other types of disease, such as breast cancer. Our results indicate these treatments may also be used for prostate cancer. "
glycans have the potential to be used as part of a diagnostic test to help doctors decide which prostate cancers need treatment.
One in eight will be diagnosed with the disease. It is the most common cancer in men in the UK, and it is necessary to identify how the disease progresses and treatment options to implement.
researchers from Newcastle University used a technique called RNA sequencing to identify the new set of genes that are important.
identified genes may provide new means of disease can be monitored in patients to predict the cancer more aggressive prostate that should be treated.
The research was funded in partnership between prostate cancer in the UK and the Movember Foundation
Simon Grieveson, head of research funding for prostate cancer in the UK , declared:. "There is a desperate need for more treatments for men with advanced prostate cancer who currently have too few options available to them.
" However, to develop new treatments effective, we need to better understand the genetic composition of aggressive prostate cancers and identify what motivates them.
"This promising research has uncovered a new group of genes that may play a role in the survival and development of cancer cells, and could open the way to new treatments in the future.
"Although this work is still in its infancy, and there is a long way to go before we have a potential new treatment, we will monitor its progress with great interest."
Dr. Munkley was awarded a Fellowship Faculty of Medical Sciences at Newcastle University to continue his research.
Like every prostate tumor is unique, future studies will look at how to use glycans as therapeutic targets for personalized treatment.
case study
A man who knows firsthand the importance of this research is David Forrester, who was diagnosed with prostate cancer ago four years.
The 62 year old had some episodes of what he thought urinary tract infections. His brother had been diagnosed with the disease in 04 and, therefore, Mr. Forrester was followed by physicians
He had annual PSA tests -. A blood test to detect early signs of an enlarged prostate - and NOT doubled in a short space of time. Mr. Forrester was referred to a urologist and underwent a biopsy confirmed that he had prostate cancer.
As a former director of the theater of operation, the grandfather of three has decided to undergo surgery to remove his prostate. Although he experienced side effects, he recovered well and enjoy life
Mr. Forrester, of West Denton, Newcastle, said :. "It is absolutely essential that the research is done in prostate cancer and experts gain understanding of the condition as possible.
" With two son and two grandchildren son, who are at higher risk of developing the disease, I am particularly interested in this research.
"the results this study offers hope to patients with prostate cancer and their families who have improved the diagnosis and treatment options will be developed in the coming years.
"it is exciting that Newcastle University leads the way and it shows what a world -class research happens. "
experts used advanced screening technique that found hundreds of genes were affected by the male hormone testosterone. It is believed this could lead to new diagnostic tests and treatments
Among the 700 genes identified is an important body that add sugar groups -. Known as glycans - on the surface of cancer cells in the prostate. This group has never been studied before.
Results of the research, published in EBioMedicine , suggest that testosterone changes glycans to make cancer cells more likely to survive, grow and spread to other parts of the body.
scientists say that there is the potential to target these glycans that could stop the growth and spread of tumors and save lives. .
Dr. Jennifer Munkley, associate researcher at the Institute of Medical Genetics, University of Newcastle, co-directed the three-year research project with Professor David Elliott
She said: "Our results are very important for future treatments because they identify a new group of molecules in prostate cancer that could be targeted therapeutically.
" now, we have identified these glycans, we will able to develop strategies to inhibit and help patients with this condition.
"processing targeting glycans sugar groups have been developed for other types of disease, such as breast cancer. Our results indicate these treatments may also be used for prostate cancer. "
glycans have the potential to be used as part of a diagnostic test to help doctors decide which prostate cancers need treatment.
One in eight will be diagnosed with the disease. It is the most common cancer in men in the UK, and it is necessary to identify how the disease progresses and treatment options to implement.
researchers from Newcastle University used a technique called RNA sequencing to identify the new set of genes that are important.
identified genes may provide new means of disease can be monitored in patients to predict the cancer more aggressive prostate that should be treated.
The research was funded in partnership between prostate cancer in the UK and the Movember Foundation
Simon Grieveson, head of research funding for prostate cancer in the UK , declared:. "There is a desperate need for more treatments for men with advanced prostate cancer who currently have too few options available to them.
" However, to develop new treatments effective, we need to better understand the genetic composition of aggressive prostate cancers and identify what motivates them.
"This promising research has uncovered a new group of genes that may play a role in the survival and development of cancer cells, and could open the way to new treatments in the future.
"Although this work is still in its infancy, and there is a long way to go before we have a potential new treatment, we will monitor its progress with great interest."
Dr. Munkley was awarded a Fellowship Faculty of Medical Sciences at Newcastle University to continue his research.
Like every prostate tumor is unique, future studies will look at how to use glycans as therapeutic targets for personalized treatment.
case study
A man who knows firsthand the importance of this research is David Forrester, who was diagnosed with prostate cancer ago four years.
The 62 year old had some episodes of what he thought urinary tract infections. His brother had been diagnosed with the disease in 04 and, therefore, Mr. Forrester was followed by physicians
He had annual PSA tests -. A blood test to detect early signs of an enlarged prostate - and NOT doubled in a short space of time. Mr. Forrester was referred to a urologist and underwent a biopsy confirmed that he had prostate cancer.
As a former director of the theater of operation, the grandfather of three has decided to undergo surgery to remove his prostate. Although he experienced side effects, he recovered well and enjoy life
Mr. Forrester, of West Denton, Newcastle, said :. "It is absolutely essential that the research is done in prostate cancer and experts gain understanding of the condition as possible.
" With two son and two grandchildren son, who are at higher risk of developing the disease, I am particularly interested in this research.
"the results this study offers hope to patients with prostate cancer and their families who have improved the diagnosis and treatment options will be developed in the coming years.
"it is exciting that Newcastle University leads the way and it shows what a world -class research happens. "
EmoticonEmoticon